March 23 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL RESULTS
AND
BUSINESS UPDATE
* GAIN THERAPEUTICS INC - $22.1 MILLION IN CASH AND CASH
EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2022
* GAIN THERAPEUTICS INC - COMPANY EXPECTS COMPLETION OF
IND-ENABLING STUDIES OF GT-02287 IN H1 2023
* GAIN THERAPEUTICS INC - SUBMISSION OF DOSSIER TO START
PHASE 1
CLINICAL TRIAL OF GT-02287 IN GBA1 PARKINSON'S DISEASE EXPECTED
BY MID-YEAR 2023
Source text for Eikon: ID:nGNX8VSz9n
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com;;))